Earnings Feed
Start Free
Home/Filings/4/0000899243-22-016383
4//SEC Filing

Versant Ventures IV, LLC 4

Accession 0000899243-22-016383

CIK 0001544227other
View on SEC.govCompany Profile

Filed

May 2, 8:00 PM ET

Accepted

May 3, 5:40 PM ET

Size

22.7 KB

Accession

0000899243-22-016383

Insider Transaction Report

Form 4
Period: 2022-04-29
Tempest Therapeutics, Inc.TPST
Versant Venture Capital VI, L.P.
10% Owner
Holdings

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    997,940

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Ventures VI GP, L.P.
10% Owner
Holdings

  • Common Stock

    997,940

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Ventures VI GP-GP, LLC
10% Owner
Holdings

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644

  • Common Stock

    997,940

  • Common Stock

    (indirect: See Footnote)
    1,171,094
Versant Vantage II, L.P.
10% Owner
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    2,118,644

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    997,940
Versant Vantage II GP, L.P.
10% Owner
Holdings

  • Common Stock

    997,940

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Vantage II GP-GP, LLC
10% Owner
Holdings

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    997,940

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Ventures IV, LLC
10% Owner
Holdings

  • Common Stock

    997,940

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Versant Venture Capital IV, L.P.
10% Owner
Holdings

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    (indirect: See Footnote)
    2,118,644

  • Common Stock

    997,940
Versant Side Fund IV, L.P.
10% Owner
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,171,094

  • Common Stock

    997,940

  • Common Stock

    (indirect: See Footnote)
    7,377

  • Common Stock

    (indirect: See Footnote)
    2,118,644
Footnotes (4)
  • [F1]These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Thomas Woiwode, a member of the Issuer's board of directors, is a managing director of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP, VV VI GP and Thomas Woiwode disclaim beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein. Thomas Woiwode is a director of the Issuer and, accordingly, files separate Section 16 reports.
  • [F2]These shares are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the general partner of VVC IV. Thomas Woiwode, a member of the Issuer's board of directors, is a managing director of VV IV and may be deemed to share voting and dispositive power over the shares held by VVC IV. Each of VV IV and Thomas Woiwode disclaim beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein. Thomas Woiwode is a director of the Issuer and, accordingly, files separate Section 16 reports.
  • [F3]These shares are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the general partner of VSF IV. Thomas Woiwode, a member of the Issuer's board of directors, is a managing director of VV IV and may be deemed to share voting and dispositive power over the shares held by VSF IV. Each of VV IV and Thomas Woiwode disclaim beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein. Thomas Woiwode is a director of the Issuer and, accordingly, files separate Section 16 reports.
  • [F4]These shares are held of record by Versant Vantage II, L.P. ("Vantage II") and the acquisition of which was reported on a Form 3 filed by Vantage II and its general partner entities on the date hereof. Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP. Thomas Woiwode, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of Vantage II GP-GP, Vantage II GP and Thomas Woiwode disclaim beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein. Thomas Woiwode is a director of the Issuer and, accordingly, files separate Section 16 reports.

Documents

1 file

Issuer

Tempest Therapeutics, Inc.

CIK 0001544227

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001456589

Filing Metadata

Form type
4
Filed
May 2, 8:00 PM ET
Accepted
May 3, 5:40 PM ET
Size
22.7 KB
View on SEC.gov